Every Form 4 that Electromed, Inc. (ELMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELMD filings page.
Electromed, Inc. (ELMD) reported that its Chief Financial Officer, Bradley M. Nagel, received equity awards on September 1, 2026. He was granted 9,600 stock options with an exercise price of $27.10 per share, scheduled to vest in three substantially equal annual installments on September 1, 2027, September 1, 2028, and September 4, 2029. He also received 4,900 shares of restricted stock, which are scheduled to vest on the same three dates. In connection with the vesting of previously awarded restricted stock, 1,102 shares were forfeited at $27.10 per share to satisfy tax withholding obligations. No Rule 10b5-1 trading plan is reported for these transactions.
Electromed, Inc. (ELMD) reported that CEO and President James L. Cunniff had 2,671 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations related to the vesting of previously awarded restricted stock. After this tax-withholding disposition, he directly holds 145,080 shares of Electromed common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Electromed, Inc. Chief Financial Officer Bradley M. Nagel reported a small share disposition related to taxes, not an open-market trade. On the reported date, 674 shares of common stock were forfeited at $42.30 per share to cover tax withholding when previously awarded restricted stock vested. After this tax-withholding event, Nagel directly held 18,964 shares of Electromed common stock, indicating the transaction was routine and left his overall ownership largely unchanged.
Electromed, Inc. CEO and President James L. Cunniff reported a combination of stock sales and an option exercise involving the company’s common stock. On June 8, 2026, he sold a total of 9,700 shares in three open-market transactions at weighted average prices of $37.7729, $36.7975, and $36.2490 per share. The same day, he exercised employee stock options to acquire 9,700 shares at an exercise price of $17.25 per share. Following these transactions, he directly holds 147,751 shares of Electromed common stock.
Electromed, Inc.’s Chief Financial Officer, Bradley M. Nagel, reported a combination of stock option exercises and share sales on June 4, 2026. He exercised options to acquire 9,601 shares of common stock at exercise prices of $10.71 and $10.25 per share, converting derivative awards into common shares.
On the same date, he sold a total of 11,801 common shares in open-market transactions, with weighted average sale prices of approximately $36.34 for 11,620 shares and $37.11 for 181 shares. After these exercises, he retained 2,633 options at an exercise price of $10.71 expiring on June 30, 2033 and 2,166 options at $10.25 expiring on November 10, 2033.
Electromed, Inc. director Kathleen Skarvan reported a combination of option exercises and share sales. On May 15, 2026, she exercised employee stock options for 40,000 shares of common stock at an exercise price of $3.82 per share.
The filing also shows four open-market sales totaling 40,000 shares of common stock on the same date, at weighted average prices of $37.33, $36.258, $35.2422, and $34.3626 per share, each executed in multiple transactions within stated price ranges. The options exercised were fully vested and related derivative positions were exhausted.
Electromed, Inc. reported an insider equity award for one of its directors. On 12/01/2025, the director acquired 3,000 shares of common stock as an award of restricted stock at a stated price of $0, reflecting a grant rather than an open-market purchase. Following this transaction, the director beneficially owns 15,000 shares directly.
The restricted stock is scheduled to vest on June 1, 2026, unless it is accelerated or terminated earlier under its terms, meaning the director’s ability to fully realize the award depends on continued satisfaction of those conditions.
Electromed, Inc. reported an insider equity grant to a director. A board member filed a Form 4 showing an acquisition of 3,000 shares of Electromed common stock on 12/01/2025 at a stated price of $0. These shares are described as restricted stock scheduled to vest on June 1, 2026, unless earlier accelerated or terminated under their terms.
After this transaction, the director beneficially owned 38,817 shares of Electromed common stock directly and 1,500 shares indirectly through Liberty Capital, LP. The filing notes that the reporting person disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest in them.
Electromed, Inc. reported a Form 4 insider transaction for a company director. On 12/01/2025, the director acquired 3,000 shares of common stock, coded as an "A" transaction, at a reported price of $0, indicating a grant rather than an open-market purchase. These shares are described as restricted stock scheduled to vest on June 1, 2026, unless earlier accelerated or terminated under their terms.
Following this grant, the director beneficially owned 21,000 shares of Electromed common stock in direct form. The filing is made by a single reporting person in the capacity of Director of Electromed.
Electromed, Inc. reported that one of its directors acquired 3,000 shares of common stock as a restricted stock award on December 1, 2025 at a stated price of $0 per share. After this award, the director beneficially owns 15,000 shares of Electromed common stock in direct ownership form. The restricted stock is scheduled to vest on June 1, 2026, unless vesting is accelerated or the award is terminated under its terms, meaning the director must remain eligible through that date to receive the shares without restrictions.
Electromed, Inc. reported an insider stock award for one of its directors. On 12/01/2025, the director acquired 3,000 shares of common stock, described as restricted stock, at a price of $0 per share. After this grant, the director beneficially owns 35,622 shares of Electromed common stock.
The restricted shares are scheduled to vest on June 1, 2026, unless they are accelerated or terminated under their terms. This filing is a routine disclosure of insider equity compensation and does not involve a public offering or sale of shares into the market.
Electromed, Inc. director and 10% owner received additional equity in the company. On December 1, 2025, the reporting person acquired 3,000 shares of Electromed common stock as restricted stock at a stated price of $0. After this grant, the reporting person holds 12,000 shares directly.
The filing also reports 270,367 shares held indirectly through Summers Value Fund LP. An explanation notes that this balance includes 100 additional shares identified through a routine reconciliation of ownership records. The 3,000 restricted shares are scheduled to vest on June 1, 2026, unless vesting is accelerated or the award is terminated under its terms.